Samarium [Sm-153] lexidronam pentasodium 3GBq/2.3ml solution for injection vials

BackgroundDrug interactions with diagnostic radiopharmaceuticals are well recognized, as they can modify biodistribution and lead to false or misleading diagnostic results. However, little is known about such interactions in the field of therapeutic radiopharmaceuticals, despite their rapid expansion-particularly with targeted radionuclide therapies such as Radioligand Therapy (RLT). This review aims, for the first time, to systematically compile and analyze available data on drug interactions involving therapeutic radiopharmaceuticals, in order to support safer and more effective patient care.Main bodyEighty-three articles investigating drug interactions with [177Lu]Lu-oxodotreotide (Lutathera®), [177Lu]Lu-vipivotide tetraxetan (Pluvicto®), [131I]INa, [131I]I-meta-iodobenzylguanidine ([131I]I-MIBG), [223Ra]RaCl2 (Xofigo®), [90Y]Y-ibritumomab tiuxetan (Zevalin®) or [153Sm]Sm-lexidronam pentasodium (Quadramet®) were included. These studies reported 133 drug interactions, 69% of which were not mentioned in the corresponding summaries of product characteristics. Interactions could be beneficial (e.g., reducing renal toxicity) or harmful (e.g., decreasing therapeutic efficacy or potentiating toxicity). Three interactions involved complementary and alternative medicines (quercetin, Ginkgo biloba and ouabain). Overall, the evidence level for reported interactions was low: 88% were classified as level 3 or 4 according to the Centre for Evidence-Based Medicine (CEBM) scale.ConclusionDrug interactions with therapeutic radiopharmaceuticals remain underreported, yet they may have significant clinical consequences. Clinical radiopharmacy plays a key role in detecting and preventing these interactions. Radiopharmacists, through their expertise, can identify potential interactions, influence therapeutic decisions, and positively impact patient management. Their involvement throughout the care pathway is essential to ensure the safe and effective use of these innovative therapies. Nuclear medicine physicians should also be aware that such interactions can alter biodistribution, compromise therapeutic efficacy, and increase the risk of adverse effects.

Abstract licence: CC BY-NC-ND

This research is proposed to identify marketing strategic of Samarium ethylenediaminetetramethylene phosphonic acid (Sm 153-EDTMP) that is used for palliative treatment of bone metastasis towards utilization policy by the Nuclear Medicine Doctors. The data is obtained from the questionnaire that were spread out to Nuclear Medicine Doctors in a number of Hospital in Indonesia as respondents. The respondents were 35 of Nuclear Medicine Doctors. This number represents 80 % of Nuclear Medicine Doctors population in Indonesia. The research methodology is accomplished by descriptive explorative analysis. The results are: (1) dose, side effect of Sm 153-EDTMP that is more tolerating than morphine, (2) according to the local product promotion, Sm 153-EDTMP is able to be delivered more effectively to the user through detailing, symposium, internet (3) the price of the local product of Sm 153-EDTMP that is way more cheaper than morphine. By paying attention to marketing strategies through product advantages, promotional forms and prices SM 153-EDTMP shows that these products can be used by Nuclear Medicine specialists (SpKN) as a palliative treatment for cancer that spreads to the bones.

Abstract licence: CC BY-NC-SA 4.0